Shandong Sinobioway Biomedicine Co Ltd - Asset Resilience Ratio
Shandong Sinobioway Biomedicine Co Ltd (002581) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Shandong Sinobioway Biomedicine Co Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2018)
This chart shows how Shandong Sinobioway Biomedicine Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Shandong Sinobioway Biomedicine Co Ltd (002581) total assets.
Liquid Assets Composition Over Time
This chart breaks down Shandong Sinobioway Biomedicine Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Shandong Sinobioway Biomedicine Co Ltd to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥100.00 | 0.0% |
| Total Liquid Assets | CN¥100.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Shandong Sinobioway Biomedicine Co Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shandong Sinobioway Biomedicine Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shandong Sinobioway Biomedicine Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
Annual Asset Resilience Ratio for Shandong Sinobioway Biomedicine Co Ltd (2018–2018)
The table below shows the annual Asset Resilience Ratio data for Shandong Sinobioway Biomedicine Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 3.03% | CN¥130.00 Million ≈ $19.02 Million |
CN¥4.29 Billion ≈ $628.26 Million |
-- |
About Shandong Sinobioway Biomedicine Co Ltd
Shandong Sinobioway Biomedicine Co., Ltd. engages in the pharmaceutical manufacturing industry in China. The company is involved in the chemical raw materials, chemical product manufacturing, and biopharmaceutical manufacturing; production and sales of medicines. It also offers operating chemical products, such as trimethyl ester and triethyl ester. The company was founded in 2000 and is based in… Read more